Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Management of local or regional non‐nodal disease
Racz, Jennifer M. , Block, Matthew S. , Baum, Christian L. , Jakub, James W. , Jakub, James W

Mayo Clinic

Journal of Surgical Oncology | December 12, 2018 | Volume: 119 | Issue: 2 | Pages: 187-199

10.1002/jso.25330 | PMID 30548554 Get It

Some melanomas develop a striking avidity for lymphatic spread. In spite of multiple recurrences, patients can remain years without visceral metastasis. There is clearly a biologic reason for this lymphotrophic pattern of growth and dissemination, which we have yet to uncover. In‐transit metastases have widely diverse clinical presentations and can be a stubborn disease to cure. As a result, a host of treatments exist that should be tailored to the individual patient.
Patient-reported activities after bilateral reverse total shoulder arthoplasties
Assenmacher, Andrew T. , Aronowitz, Jessica G., Kergosien, Matthew, Schleck, Cathy D. , Cofield, Robert H. , Sperling, John W. , Alentorn-Geli, Eduard, Aronowitz, Jessica, Sanchez-Sotelo, Joaquin, Alentorn‐Geli, Eduard , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Surgery | December 10, 2018 | Volume: 27 | Issue: 1 | Pages: No page available

10.1177/2309499018816771 | PMID 30526285 Get It

Purpose: Reverse shoulder arthroplasty (RSA) improves pain and function with very good satisfaction. Concerns exist about some activities of daily living (ADLs) involving internal rotation. The purpose of this study was to report how patients with bilateral RSA perform various ADLs. Methods: Thirty-one primary bilateral RSA patients (average age 76 years; 21 women and 10 men) completed a survey to assess various outcomes. The average time between the second arthroplasty and the survey was 2.7 years (range 1.0–7.8 years). Results: All clinical parameters were favorable. All patients reported being able to easily manage toileting and 87% reaching their back pocket. However, 29% found difficulty and 39% were unable to wash their back or put on bra. In comparison with various unilateral arthroplasty types, there was no statistical difference in overall activities ( p < 0.05). Conclusion: Bilateral RSA can provide good functional outcome and high satisfaction. Patients manage most ADLs easily with some limitations in activities requiring extreme internal rotation.
Arterial involvement in Erdheim–Chester disease
Villatoro‐Villar, Michel , Bold, Michael S., Warrington, Kenneth J. , Crowson, Cynthia S. , Goyal, Gaurav , Goyal, Guarav , Warrington, Kenneth J , Shah, Meera , Go, Ronald S. , Koster, Matthew J.

Mayo Clinic

Medicine | December 8, 2018 | Volume: 97 | Issue: 49 | Pages: e13452

10.1097/md.0000000000013452 | PMID 30544428 Get It

Abstract Erdheim-Chester disease (ECD) is a rare histiocytosis of the “L” (Langerhans) group with multisystem involvement that can affect the large and medium-sized arteries mimicking vasculitis. Aortic involvement is common but the frequency and outcome of aortic branch vessel abnormalities are less well described. Patients with ECD were retrospectively identified. Images containing information of arterial involvement within 6 months of diagnosis were considered baseline and compared to last follow-up studies. Two physicians independently reviewed the studies to evaluate for presence of abnormalities attributable to ECD. Age and sex-adjusted logistic regression models were used to examine associations between patient characteristics and vessel involvement at baseline. Among a cohort of 64 patients with ECD, 63 had baseline imaging of vascular structures. ECD involvement of at least 1 segment of the aorta was observed in 56%. Abnormalities were also observed in aortic arch branches (26%), visceral branch arteries (40%), iliofemoral arteries (31%), coronary (5%), and pulmonary (3%) arteries. Perinephric fibrosis was strongly associated with the identification of abnormalities in the thoracic aorta (OR 4.92 [1.54, 15.75]; P = .007), abdominal aorta (OR 7.57 [2.28, 25.07]; P = .001) and visceral branch arteries (OR 6.05 [1.52, 24.03]; P = .01) but not pelvic/lower extremity arteries. Complete normalization of arterial abnormalities at follow-up was only observed in 9% or less of arterial segments involved at baseline. Aortic and aortic branch vessel abnormalities are frequently observed in patients with ECD and are often asymptomatic. Partial and/or complete resolution of arterial findings is uncommon.
Radiation Therapy for Retroperitoneal Sarcomas: Influences of Histology, Grade, and Size
Leiting, Jennifer L. , Bergquist, John R. , Merrell, Kenneth W. , Folpe, Andrew L. , Robinson, Steven I. , Nagorney, David M. , Truty, Mark J. , Grotz, Travis E. , Robinson, Steven I , Grotz, Travis E , Leiting, Jennifer L , Bergquist, John R , Hernandez, Matthew C.

Mayo Clinic

Sarcoma | December 5, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/7972389 | PMID 30631245 Get It

Perioperative radiation therapy (RT) has been associated with reduced local recurrence in patients with retroperitoneal sarcomas (RPS); however, selection criteria remain unclear. We hypothesized that perioperative RT would improve survival in patients with RPS and would be associated with pathological factors. The National Cancer Database (NCDB) from 2004 to 2012 was reviewed for patients with nonmetastatic RPS undergoing curative intent resection. Tumor size was dichotomized at 15 cm based on 8th edition American Joint Committee on Cancer (AJCC) staging. Patients with the highest comorbidity score were excluded. Unadjusted Kaplan–Meier and adjusted Cox proportional hazards modeling analyzed overall survival (OS). Multivariable logistic regression modeled margin positivity. A total of 2,264 patients were included; 727 patients (32.1%) had perioperative radiation in whom 203 (9.0%) had radiation preoperatively. Median (IQR) RPS size was 17.5 [11.0–27.0] cm. Histopathology was high grade in 1048 patients (43.7%). Multivariable analysis revealed that perioperative radiation was independently associated with decreased mortality (HR 0.72, 95% confidence intervals (CIs) 0.62–0.84,p<0.001), and preoperative RT was associated with reduced margin positivity (HR 0.72, 95% CI 0.53–0.97,p=0.032). Stratified survival analysis showed that radiation was associated with prolonged median OS for RPS that were high-grade (64.3 vs. 43.6 months,p<0.001), less than 15 cm (104.1 vs. 84.2 months,p=0.007), and leiomyosarcomatous (104.8 vs. 61.8 months,p<0.001). Perioperative radiation is independently associated with decreased mortality in patients with high-grade, less than 15 cm, and leiomyosarcomatous tumors. Preoperative radiation is independently associated with margin-negative resection. These data support the selective use of perioperative radiation in the multidisciplinary management of RPS.
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1
Block, Matthew S. , Nevala, Wendy K. , Pang, Yuan‐Ping , Allred, Jacob B., Strand, Carrie , Pang, Yuan-Ping , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | December 5, 2018 | Volume: 29 | Issue: 4 | Pages: 420-427

10.1097/cmr.0000000000000556 | PMID 30520800 Get It

A vaccine that could expand melanoma-specific T cells might reduce the risk of recurrence of resected melanoma and could provide an alternative or adjunct to standard immunotherapy options. We tested the safety and immunogenicity of a vaccine coupling a melanoma-associated peptide with a xenogenic peptide (to promote epitope spreading) and/or resiquimod (to activate antigen-presenting cells). HLA-A2-positive patients with resected stage II, III, and IV melanoma were assigned to treatment on one of three schedules. All patients received three subcutaneous doses of the peptide MART-1a mixed with Montanide. In addition, patients on schedule 1 received the xenoantigen peptide Gag267–274, patients on schedule 2 received topical resiquimod, and patients on schedule 3 received both Gag267–274 and resiquimod. Blood samples were tested for the frequency of antigen-specific T cells by tetramer assay, as well as immune cell subtypes and plasma cytokine levels. Patients enrolled from October 2012 to December 2014, with 10 patients enrolling to each schedule. The most common adverse events were injection site reaction (26 patients) and fatigue (15 patients). Tetramer analysis revealed antigen-specific responses (defined as doubling of MART-1a-specific T cells from pretreatment to post-treatment) in 20, 60, and 40% of patients treated on schedules 1, 2, and 3, respectively. Vaccine treatment consisting of MART-1a peptide, Gag267–274, Montanide, and topical resiquimod was well-tolerated. The addition of the Gag267–274 xenoantigen was not associated with an increase in the response to MART-1a, whereas use of topical resiquimod was associated with a higher frequency of MART-1a-specific T-cell responses that did not meet statistical significance.
Assessment of Test Performance and Potential for Environmental Contamination Associated with a Point-of-Care Molecular Assay for Group A Streptococcus in an End User Setting
Myhre, Nikki K., Murray, Martha A. , McDonah, Margaret R. , Myers, Jane F., Maxson, Julie, Meek, Alicia M., Espy, Mark J., Furst, Joseph W. , Karon, Brad S. , Binnicker, Matthew J. , Donato, Leslie J. , Maxson, Julie A, Myhre, Nikki K.

Mayo Clinic

Journal of Clinical Microbiology | December 4, 2018 | Volume: 57 | Issue: 2 | Pages: No page available

10.1128/jcm.01629-18 | PMID 30518542 Get It

Although U.S. Food and Drug Administration-approved and CLIA-waived point-of-care (POC) molecular systems are being implemented in routine clinical practice, instrument reliability, test performance in the hands of end users, and the potential for environmental contamination resulting from use of POC molecular systems have not been extensively evaluated.
Surgical Care for Women with Endometrial Cancer in Florida
DeStephano, Christopher C. , Cochuyt, Jordan J., Robertson, Matthew A. , Spaulding, Aaron , Colibaseanu, Dorin T, Spaulding, Aaron C. , Spaulding, Aaron , Osagiede, Osayande , Colibaseanu, Dorin , Robertson, Matthew A.

Mayo Clinic

Journal of Gynecologic Surgery | December 3, 2018 | Volume: 35 | Issue: 3 | Pages: 163-171

10.1089/gyn.2018.0086 | PMID 31289427 Get It

Book Review: Rowan's Primer of EEG, Second Edition
Hoerth, Matthew T.

Mayo Clinic

Journal of Clinical Neurophysiology | November 29, 2018 | Volume: 36 | Issue: 3 | Pages: 246-246

10.1097/wnp.0000000000000531 Get It

The cost implications of palliative radiation therapy dose and fractionation for painful metastatic bone lesions.
Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , Jenkins, Mikayla, Pacitti, Delaney, DeVries, Matthew , Patibandla, Aditya, May, Jackson, White, Launia J. , Spaulding, Aaron , Naessens, James M. , Keole, Sameer R., Spaulding, Aaron , Daniel, J. , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 145-145

10.1200/jco.2018.36.34_suppl.145 Get It

145 Background: Palliative radiation treatment (pRT) is used for symptomatic bone metastases (mets). Several fractionation schedules show equal efficacy for pain relief, and ASTRO’s Choosing Wisely recommends 8Gy x1, 4Gy x5, or 3Gy x10. This study aims to investigate the cost implications of pRT for bone mets. Methods: Patients (Pts) treated with pRT for bone mets at Mayo Clinic from 2007 - 2016 were included in this study. Costs for all services were subdivided into RT and total costs at 30 & 90 days (30D & 90D). Standardized costs were obtained from the Mayo Clinic Cost Data Warehouse and Medicare reimbursements were assigned to all services with cost to charge adjustments and 2017 GDP Implicit Price Deflator for inflation. Cost means were compared via the Kruskal-Wallis test. Results: 538 pts were treated with pRT, 124 receiving 8Gy x1, 204 receiving 4Gy x5, and 210 receiving 3Gy x10. Pts with breast and prostate cancer were most likely to be treated with 3Gy x10 and pts with GI and lung cancer were most likely to be treated with 8Gy x1. RT costs at 30D were $1,497, $1,891, and $1,982 (p=0.03) and RT costs at 90D were $2,602, $2,753, and $3,032 (p=0.08) for initial RT regimens of 8Gy x1, 4Gy x5, and 3Gy x10. Total costs of care at 30D were similar from $15,969 - 17,687 (p=0.6) and total costs at 90D were similar from $22,361 - 23,219 (p=0.7) between arms. A total of 23%, 28%, and 39% of pts were alive 2 years following pRT from each arm (p=0.07). Conclusions: This is the first study of its kind to analyze actual treatment costs for the three most common pRT regimens in bone mets. Single fraction RT was most used for pts with poor prognoses and was associated with lower RT costs at 30D, but similar RT costs at 90D, possibly due to retreatment. RT choice had no impact on overall costs of care at 30D or 90D. pRT remains of high value, representing only 11-13% of total costs.[Table: see text]
Toxicity following palliative radiation therapy for painful metastatic bone lesions.
Jenkins, Mikayla, Waddle, Mark R. , Kaleem, Tasneem , Stross, William C. , Malouff, Timothy D. , DeVries, Matthew , Pacitti, Delaney, May, Jackson, Patibandla, Aditya, White, Launia J. , Spaulding, Aaron , Naessens, James M. , Spaulding, Aaron , Miller, Robert C.

Mayo Clinic

Journal of Clinical Oncology | November 28, 2018 | Volume: 36 | Issue: 34_suppl | Pages: 126-126

10.1200/jco.2018.36.34_suppl.126 Get It

126 Background: Palliative radiation treatment (pRT) is a common and effective treatment for patients with symptomatic bone metastases. However, patients receiving RT for bone metastases often may have a poor performance status and are more likely to experience toxicity during or after treatment. This study aims to investigate the number and type of toxicity event occurring during or after pRT for bone metastases. Methods: Patients treated with RT for bone metastases at Mayo Clinic from 2007 to 2016 were included in this study. Demographic, disease, treatment, and toxicity information were collected. Specifically, toxicity events were identified as emergency department (ED) visits and inpatient hospitalization (IH) within 90 days, breaks in treatment >4 days, and excessive 30 day financial toxicity defined as standardized Medicare costs >1 standard deviation above the mean. RT treatment was compared by dose and fractionation via descriptive statistics. Results: A total of 538 patients treated with pRT were identified, 124 receiving 8Gy x1, 204 receiving 4Gy x5, and 210 receiving 3Gy x10. Patients with breast and prostate cancer were most likely to be treated with 3Gy x10 and patients with GI and Lung cancer were most likely to be treated with 8Gy x1. A description of the patient characteristics and toxicities are shown in Table 1. For 8Gy x1, 4Gy x5, and 3Gy x10 breaks in treatment were rare (0%, 2%, and 3.3%), ED visits (15%, 24%, & 28%), IH (12%, 23%, & 19%), and financial toxicity (13%, 18%, & 21%) were common. A total of 22.6%, 27.5%, and 38.6% of patients were alive two years following pRT from each group. Conclusions: Toxicity during or shortly after pRT of bone metastases is common. This study confirms that additional steps should be taken to monitor and mitigate toxicity in this vulnerable patient group. [Table: see text]